Send to:

Choose Destination
See comment in PubMed Commons below
Bull Cancer. 2014 May 1;101(5):438-44. doi: 10.1684/bdc.2014.1945.

[Squamous cell carcinoma of the hypopharynx and larynx: evidence-based care].

[Article in French]

Author information

  • 1Université de Lyon, Centre Léon-Bérard, Service de médecine, 28, rue Laennec, 69008 Lyon, France.
  • 2Centre Jean-Bernard, Clinique Victor-Hugo, Service de radiothérapie, 9, rue Beauverger 72000 Le Mans, France.
  • 3Centre hospitalier universitaire Vaudois, Service de radiothérapie, 46, rue du Bugnon, 1011 Lausanne, Suisse.
  • 4Centre Oscar-Lambret, Service de chirurgie maxillofaciale, 3, rue Frédéric-Combemale, 59000 Lille, France.


Squamous cell carcinomas of larynx and hypopharynx can be treated by surgery and/or radiotherapy according to tumor size. For small tumors, the results are similar. For locally advanced tumors, the surgical approach is mutilating and requires a total (pharyngo)laryngectomy. Exclusive chemoradiotherapy has shown its interest at the cost of late sequelae. In order to reduce these effects and mutilation, induction chemotherapy with cisplatin, docetaxel and 5FU for organ preservation becomes the standard treatment but there are no solid studies comparing this approach with the exclusive chemoradiotherapy. And it is not possible to conclude as to the superiority of a scheme in terms of overall survival. When chemotherapy is chosen, the modalities of any potentiation of radiation have not been yet established.


TPF; chemoradiotherapy; hypopharynx; induction; larynx

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk